Drop in PSA Tied to Better Outcomes of Apalutamide Therapy in Prostate Cancer
Adding apalutamide to androgen-deprivation therapy leads to a fast, sustained drop in PSA levels in patients with nonmetastatic castration-resistant prostate cancer, and this reduction is linked with better outcomes, according to a post hoc analysis of data from the SPARTAN trial.
Reuters Health Information
source https://www.medscape.com/viewarticle/965785?src=rss
Reuters Health Information
source https://www.medscape.com/viewarticle/965785?src=rss
Comments
Post a Comment